Calcium Citrate

Summary

Calcium Citrate (CHEMBL2106123) is a phase-3 clinical-stage small-molecule nutraceutical (ATC A12AA13); indicated across 1 condition including dental caries.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A12AA13
• Indications: 1 condition
• Clinical trials: 10
• Chemistry: 498.4 Da · C12H10Ca3O14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2106123
Name	Calcium Citrate
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	13136
ChEBI	CHEBI:190513
ATC	A12AA13
Molecular formula	C12H10Ca3O14
Molecular weight	498.4
InChIKey	FNAQSUUGMSOBHW-UHFFFAOYSA-H

SMILES: C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Ca+2].[Ca+2].[Ca+2]

IUPAC name: tricalcium bis(2-hydroxypropane-1,2,3-tricarboxylate)

ChEBI definition: An organic calcium salt composed of calcium cations and citrate anions in a 3:2 ratio.

Pharmacological roles (ChEBI): nutraceutical.

Other ChEBI roles (chemical / environmental): food additive, food preservative, flavouring agent.

Also known as: Calcimax, Calcium (as citrate), Calcium citrate, Calcium citrate anhydrous, Calcium citrate tetrahydrate, Citracal, E-333(III), INS NO.333(III), INS-333(III), Tricalcium citrate tetrahydrate, Tricalcium dicitrate tetrahydrate, CALCIUM CITRATE

Patent coverage: 14,604 distinct patent families (39,984 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
dental caries	0	MONDO:0005276	EFO:0003819

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE4	4
Not specified	3
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01400516	PHASE4	COMPLETED	Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
NCT01731340	PHASE4	COMPLETED	A Study on the Impact of Calcium on Woman’s Vascular Health
NCT03424239	PHASE4	COMPLETED	Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
NCT03425747	PHASE4	COMPLETED	Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism
NCT00354302	PHASE3	COMPLETED	Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
NCT00416715	PHASE2	COMPLETED	Vitamin D Deficiency, Muscle Pain, Joint Pain, and Joint Stiffness in Postmenopausal Women Receiving Letrozole For Stage I-III Breast Cancer
NCT01317940	PHASE2	COMPLETED	Nutrition and Body Composition in Acute Lymphoblastic Leukemia
NCT00145977	Not specified	COMPLETED	Texture Analysis for Postmenopausal Osteoporosis
NCT02830789	Not specified	COMPLETED	Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass
NCT03232034	Not specified	COMPLETED	Calcium, Protein and Gut Hormones

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).